Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
Building on Part I of the stigma webinar series and its introduction of a statewide collective impact model for addressing stigma, this webinar delivered the first part of the model that also served as its conceptual framework. This webinar introduced the stages of change and showed grantees how these apply to their target populations. We also discussed how those same principles applied to grantee engagement of community stakeholders and their openness to evidence-based practices that reduce morbidity and mortality related to SUD/OUD.
Posted 4/5/2024
The report Financing Peer Recovery Support: Opportunities to Enhance the Substance Use Disorder Workforce was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Financing Reform and Innovation (CFRI) and provides background history of the development of Peer Recovery (PR), including an overview of the current landscape of PR Programs. This report also provides a description of the variation in peer recovery rates, supervision, credentialing, and substance use disorder vs mental health.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.
Posted 6/26/2020 (updated 3/28/2024)
This report presents information about Medicaid coverage of medication-assisted treatment for opioid and alcohol dependence. It covers treatment effectiveness and cost effectiveness. The report also offers examples of innovative approaches in Vermont, Massachusetts, and Maryland.
Posted 8/24/2020 (updated 3/28/2024)
Syringe service programs (SSPs), which provide access to sterile syringes and other injection equipment and their safe disposal after use,* represent a highly successful human immunodeficiency virus (HIV) prevention intervention. SSPs are associated with a 58% reduction in the incidence of HIV infection among persons who inject drugs. In addition, SSPs have led efforts to prevent opioid overdose deaths by integrating evidence-based opioid overdose education and naloxone distribution (OEND) programs. OEND programs train laypersons to respond during overdose events and provide access to naloxone and directions for drug delivery. SSPs are ideal places for OEND because they provide culturally relevant services designed to reach persons at high risk for experiencing or observing an opioid overdose.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 2/2/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services' Office of Minority Health provided a brief in November 2023 assessing whether and how rates of substance use and substance use disorder (SUD) among adults (ages 18 and older) differ by race and ethnicity.
Posted 1/16/2024 (updated 3/28/2024)
The Annie E. Casey Foundation has published the 2023 Kids Count Data Book: State Trends in Child Well-Being.
Posted 7/17/2020 (updated 3/28/2024)
Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%–22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.